Vanda Pharmaceuticals (VNDA) 10-K2017 FY Annual report

Filed: 15 Feb 18, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: aberrant, agomelatine, Allergan, argument, Article, auditor, baseline, breakup, bribery, burden, California, CFTR, Columbia, commonplace, compromise, constipation, countervailing, Cybersecurity, Cystic, deviate, deviation, disparate, distributor, dry, error, exit, eye, FileNo, Fisher, Francisco, gave, Gunther, HETLIOZ®that, HETLIOZ®third, Hikma, HITECH, Hospitalized, includingcurrent, insensitive, inthe, invoke, isolation, itch, kidney, leaving, licensor, Lisbon, migration, millionfor, millionin, millionof, minister, misleading, neurological, onmanufacturing, onSanofi, oppose, opposed, parliament, PCAOB, PDMA, perception, PhaseII, physical, physiological, polycystic, precipitate, predisposing, prime, privacy, provoke, proximity, psychiatric, punishable, quantify, question, reclassify, recoverable, referendum, refining, refractory, relapsed, relieve, remeasured, remeasurement, reply, rulemaking, San, secretory, sighted, simulated, slowdown, taxation, TCJA, tendency, TheNasdaq, theOrange, Thermo, tomanufacturing, tothe, TotheBoard, Transmembrane, transmeridian, transparency, travel, Treaty, UCSF, underperformance, University

Removed: acquiree, add, agemelatine, alleviate, Baroldi, building, campaign, CINV, commencing, complied, consumed, cure, de, deducting, Description, developmental, disclose, doubt, duration, exacerbate, exchanged, forfeiture, formal, HMRI, Hoechst, introduce, irrevocably, line, lingering, MAA, margin, Marion, obsolescence, overstating, Paolo, pharmacovigilance, PONV, predecessor, Preferability, premium, Probiomed, ratably, reacquire, reacquisition, released, Roussel, scenario, SCN, settled, sharing, straight, Subtopic, supporting, timeframe, understating, underwriting, unstable, variability, waive, waived, windfall, withdrew

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated VNDA transcripts

VNDA similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the Registration Statements on FormsS-8 (No.333-133368,No. 333-138070,No. 333-141571,No. 333-148924,No. 333-156995,No. 333-164567,No. 333-171962,No. 333-179265,No. 333-186509,No. 333-193614,No. 333-201754,No. 333-209144,No. 333-212255 andNo. 333-218774) and on FormS-3(No. 333-205513) of Vanda Pharmaceuticals Inc. of our report dated February 15, 2018 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form10-K.

/s/ PricewaterhouseCoopers LLP

Baltimore, Maryland

February 15, 2018